Palm Tocotrienol Deemed Safe in Subjects with Metabolic Syndrome

03 Jan 2017 --- Subjects with metabolic syndrome can supplement with 400mg palm tocotrienol complex for 14 days without any adverse health impact on blood profile (e.g. haematoxicity) and liver functions (e.g. hepatotoxicity), according to a new randomized, double-blind, cross-over and placebo-controlled clinical trial.

The research looked specifically at EVNol SupraBio, supplied by ExcelVite. The company hopes that the new results may contribute to the scientific community in the establishment of intake recommendations for tocotrienols, particularly the tolerable upper intake levels.

The study looked at 31 subjects with metabolic syndrome aged between 25 and 56 years old. Each participant was randomly assigned to receive either 400mg of palm tocotrienol complex (EVNol SupraBio) or a placebo for 14 days. This was followed by the measurement of body weight, haematological profile (ie: physiology of the blood) and liver functions examination.

When compared to placebo, subjects supplemented with EVNol SupraBio (patented bio-enhanced natural full spectrum palm tocotrienol complex) demonstrated no negative effects on red blood cells (RBC), white blood cells (WBC) and platelet counts.

Additionally, patients under EVNol SupraBio treatment did not show significant difference in body weight, and serum liver enzymes such as aspartate aminotransferase (AST), alanine aminotransferase (ALT) and albumin.

Collectively, EVNol SupraBio is well tolerated with no toxicity issue such as no report of weight loss, bleeding tendency or interference with the haemostasis status. In addition, EVNol SupraBio also does not affect liver function nor increase the risk of hepatotoxicity.

The study is not the first to back the safety of EVNol SupraBio supplementation.

“Apart from this study, another recent clinical study also reveals that daily supplementation of 400mg of d-mixed tocotrienol (EVNol SupraBio) for 52 weeks demonstrates fatty liver amelioration in non-alcoholic-induced fatty liver subjects, without any reported adverse health effects,” says CheeYen Lau, Nutritionist of ExcelVite.

“Fatty liver is the precursor to metabolic syndrome (eg. diabetes, obesity and hypertension) and these encouraging clinical results allows companies to formulate a liver health product with EVNol SupraBio to address fatty liver.”

“Not all tocotrienol are created equal. In fact, EVNol SupraBio - manufactured by ExcelVite is the only GMP-certified tocotrienol complex in the world,” explains Lau.

“EVNol SupraBio has been used in more than 15 human clinical studies for different endpoints and health benefits such as brain protection, cardiovascular health (e.g. healthy cholesterol level and arterial compliance), liver health as well as skin and hair growth.”

“This is the first human clinical study that evaluates the safety of tocotrienol in terms of haematological and hepatological profiles vis a vis proven safety results of EVNol SupraBio,” adds Lau.